CEL-SCI Corp
F:LSRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CEL-SCI Corp
F:LSRM
|
US |
|
C
|
China Construction Bank Corp
DUS:C6T
|
CN |
|
K
|
Kawasaki Kisen Kaisha Ltd
TSE:9107
|
JP |
|
V
|
Vale SA
XBER:CVLC
|
BR |
|
T
|
Titanium Transportation Group Inc
TSX:TTNM
|
CA |
|
Chandra Asri Petrochemical Tbk PT
OTC:PTCAY
|
ID |
|
Takasago Thermal Engineering Co Ltd
F:Q74
|
JP |
|
S
|
Shopify Inc
TSX:SHOP
|
CA |
CEL-SCI Corp
CEL-SCI is a biotechnology company focused on developing cancer treatments that help the immune system fight tumors. Its best-known product candidate is Multikine, an immune-based therapy designed for patients with advanced head and neck cancer before they receive standard surgery, radiation, or chemotherapy. The company also has other early-stage immunotherapy research, but its core identity is tied to this one lead drug program. CEL-SCI does not sell a broad line of commercial medicines like a large drugmaker. It mainly spends money on research, clinical trials, and the regulatory work needed to get a new therapy approved. If its lead program succeeds, the company would make money by selling or partnering its treatment with hospitals, cancer centers, or a larger pharmaceutical company that could help market and distribute it. What makes CEL-SCI different is its role as a drug developer rather than a drug manufacturer or distributor. It is trying to move one specialized therapy through the high-risk, highly regulated path from lab research to patient use. That makes the business much more dependent on clinical trial results and regulatory decisions than on steady product sales.
CEL-SCI is a biotechnology company focused on developing cancer treatments that help the immune system fight tumors. Its best-known product candidate is Multikine, an immune-based therapy designed for patients with advanced head and neck cancer before they receive standard surgery, radiation, or chemotherapy. The company also has other early-stage immunotherapy research, but its core identity is tied to this one lead drug program.
CEL-SCI does not sell a broad line of commercial medicines like a large drugmaker. It mainly spends money on research, clinical trials, and the regulatory work needed to get a new therapy approved. If its lead program succeeds, the company would make money by selling or partnering its treatment with hospitals, cancer centers, or a larger pharmaceutical company that could help market and distribute it.
What makes CEL-SCI different is its role as a drug developer rather than a drug manufacturer or distributor. It is trying to move one specialized therapy through the high-risk, highly regulated path from lab research to patient use. That makes the business much more dependent on clinical trial results and regulatory decisions than on steady product sales.
